A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum
NCT01965613 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2025-07-08
Summary
The purpose of this study is to determine if treatment with Xionix will improve wound healing for patients with pyoderma gangrenosum.
Conditions
- Pyoderma Gangrenosum
Interventions
- BIOLOGICAL
-
Xilonix
IV
Sponsors & Collaborators
-
Janssen Research & Development, LLC
lead INDUSTRY
Principal Investigators
-
Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-01-31
- Primary Completion
- 2016-12-31
- Completion
- 2016-12-31
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis
NCT06119490 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
NCT04837131 ·Status: TERMINATED ·Phase: PHASE2
-
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
NCT05189925 ·Status: RECRUITING ·Phase: PHASE1
-
Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
NCT02037347 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita
NCT00716014 ·Status: COMPLETED ·Phase: PHASE1
-
Identifying Factors Influencing In-Hospital Relapse in Pemphigus Patients
NCT06167408 ·Status: COMPLETED
-
Retrospective Study of the Effects of Sub-pathologic Phenotypes of BP on Clinical Management and Prognosis
NCT06213909 ·Status: RECRUITING
-
A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome
NCT05211830 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Nilotinib in the Treatment of Systemic Sclerosis
NCT01166139 ·Status: COMPLETED ·Phase: PHASE2
-
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
NCT02960997 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of D-Fi for the Treatment of Wounds Due to DEB
NCT06892639 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
NCT04213261 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of the Safety and Tolerability of MEDI-551 in Scleroderma
NCT00946699 ·Status: COMPLETED ·Phase: PHASE1
-
Use of an SPF30 Sunscreen and an After-sun-lotion in Skin Cancer Risk Patients
NCT00555633 ·Status: COMPLETED
-
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
NCT05149768 ·Status: RECRUITING ·Phase: PHASE2
-
Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum
NCT03636737 ·Status: UNKNOWN
-
Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa
NCT03578029 ·Status: TERMINATED ·Phase: PHASE2
-
Autoimmune Blistering Diseases Study
NCT02753777 ·Status: RECRUITING
-
Studies of Dermatologic Diseases Biospecimen Acquisition Protocol
NCT02471352 ·Status: RECRUITING
-
Short Term Observational Study in DEB Patients
NCT02178969 ·Status: COMPLETED
-
Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects
NCT05844293 ·Status: RECRUITING ·Phase: PHASE1
-
Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN
NCT06474078 ·Status: COMPLETED ·Phase: NA
-
The Ohio State University Dermatology Biorepository
NCT03146676 ·Status: RECRUITING
-
A Phase 2 Study With CC-220 in Skin Sarcoidosis
NCT02192489 ·Status: WITHDRAWN ·Phase: PHASE2
-
JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
NCT04792957 ·Status: UNKNOWN